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Characteristics of Patients with High on-Treatment Platelet Reactivity
High Residual
Platelet
Reactivity
(n=361)
Therapeutic
Platelet
Reactivity
(n=1144) p-value
Presentation
characteristics
Age, years, median
(IQR)
62 (55,69) 59 (52,66) <0.001
Female sex 39.3% 26.5% <0.001
BMI, kg/m2, median
(IQR)
29.9 (26.7,34.2) 29.1 (25.8,33.0) 0.002
Diabetes 39.3% 23.3% <0.001
Prior MI 20.5% 16.8% 0.12
Prior PCI 28.0% 21.9% 0.02
Current/recent
smoker
33.2% 36.8% 0.18
STEMI on
presentation
48.8% 54.3% 0.07
Home ADP receptor
inhibitor use
15.8% 11.0% 0.02
In-hospital
management
Drug-eluting stent use 72.3% 78.3% 0.02
Multivessel PCI 10.8% 11.6% 0.67
2nd generation ADP
receptor inhibitor
prescribed at
discharge
40.4% 36.3% 0.15
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Background: It is well known that platelet volume indices are associated with adverse
outcomes after percutaneous coronary intervention (PCI). In this study, we investi-
gated the hypothesis whether association between platelet size and clinical outcomes
were due to antiplatelet hyporesponsiveness in patients with large platelets.
Methods: Between Feb 2010 and Dec 2011, a total of 462 consecutive patients with
coronary artery disease and planned PCI were enrolled. Before PCI, all patients
received 300mg aspirin and 300mg clopidogrel. The arachidonic acid (AA) and
adenosine diphosphate (ADP) induced platelet aggregation were assessed in whole
blood with the Multiple Electrode Platelet Aggregometry (Multiplate, Dynabyte,
Munich, Germany) (MEA) test. We simultaneously measured mean platelet volume
(MPV) in the same period (Sysmex XE-2100, Mundelein, IL). Major adverse
cardiovascular events (MACEs) were deﬁned as composites of cardiac death,
myocardial infarction, stroke, and target vessel revascularization. Median follow up
duration was 18.8 months and follow up loss rate was 1.3%.
Results: Our population is represented by 462 consecutive patients composed of 371
stable angina patients and 91 acute coronary syndrome patients. All patients had
successful PCI and underwent dual antiplatelet therapy for at least 6 months. Patients
with large platelets (upper quintile of MPV, 10.6 fL) were signiﬁcantly associated
with hyporesponsiveness to both aspirin (MEA ASP 9 [5-14] Units vs. 13 [8-18.5]
Units, p<0.001) and clopidogrel (MEA ADP 21 [15-30] Units vs. 24 [18.5-40] Units,
p¼0.003). On multivariate analysis, the patient group with large platelets was inde-
pendently associated with both aspirin (OR 2.52, 95% CI 1.50 – 4.24, p<0.001) and
clopidogrel (OR 2.86, 95% CI 1.59 – 5.15, p<0.001) hyporesponsiveness. 17 patients
(3.68 %) had MACEs during the follow up period. Platelet volume indices were not
associated with any differences in the incidence of MACEs.
Conclusions: Platelets with higher volume are associated with hyporesponsiveness to
conventional dual antiplatelet therapy. Further studies are warranted to clarify its
association with clinical outcomes.
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Background: Performance characteristics of the TAXUS Liberté stent in diabetic
(DM) patients when combined with second-generation thienopyridine anti-platelet
drugs are unknown.
Methods: As part of the TAXUS Liberté paclitaxel-eluting stent post-approval study,
a pre-deﬁned subgroup of medically treated DM pts with "on-label" indications (i.e.,
treated as per FDA-approved labeling) for coronary stent use was studied. All were
prescribed aspirin + prasugrel. The primary endpoint was target vessel failure (TVF) at
12 months; based on prior studies, the expected TVF rate was 9.0% and the perfor-
mance limit for non-inferiority was 12.6%. In addition, outcomes were compared with
"on-label" non-diabetic (NDM) pts.
Results: Of 1592 enrolled pts meeting "on-label" criteria, 505 (31.7%) were dia-
betic: 68% male, mean age 60.6 years, 19.8% smoked, 39.4% presented with stable
angina, 31.9% unstable angina, 0.6% NSTEMI (none with STEMI). More than 99%
had a de novo lesion treated. Lesion types B2 and C were 14.1 and 8%. The primary
endpoint of TVF occurred in 25 (5.1%) DM pts; the upper 1-sided 95% conﬁdence
interval was 6.8%, well below the performance limit of 12.6% (p<0.0001). Four
deaths (0.8%, none attributable to the TAXUS Liberté stent), 4 NSTEMI, and 3
strokes were observed. Major bleeding occurred in 8 (1.6%) and stent thrombosis
occurred in 1 pt. Compared with NDM, DM pts were more likely to be overweight,
have metabolic syndrome, hyperlipidemia and hypertension but less likely to
smoke. Lesion complexities were similar but DM vessels were smaller and NDM
lesions longer and more likely to contain thrombus. TVF and clinical outcomes,
including GUSTO moderate or severe bleeding, were similar for DM and NDM
patients.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: We observed low rates of TVF at 1 year during post-approval clinical
use of TAXUS Liberté PES in DM pts with "on-label" indications and taking aspirin +
prasugrel. TVF and clinical outcomes were similar to those observed among NDM pts.
Bleeding rates were low for "on-label" DM and NDM patients. These data suggest
potential beneﬁt with use of second-generation PES combined with ASA and prasu-
grel in selected DM pts including those without acute coronary syndromes.
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Background: High platelet reactivity (HPR) on ADP receptor inhibitor treatment
(ADPri) is associated with increased risk of adverse events, yet there are no guidelines
on its management.
Methods: We studied 1,505 acute MI patients treated with PCI at 62 US hospitals in
the TRANSLATE-ACS study from 4/2010 to 10/2012. All patients received either
a 1st generation (clopidogrel or ticlopidine) or 2nd generation (prasugrel or ticagrelor)
ADPri and underwent platelet reactivity testing using the VerifyNow assay at
a median of 2 days after PCI. We used logistic regression modeling to determine
factors associated with HPR (platelet reactivity unit [PRU] >235), and examined rates
of treatment change in response to platelet function testing.
Results: Overall, HPR was observed in 361 (24%) of this acute MI population, more
frequently among patients treated with 1st generation (29%) than those treated with
2nd generation ADPri (7%). HPR was independently associated with patient age (OR
1.18, 95%CI 1.04-1.34, per 10 year increase, p¼0.01), female sex (OR 1.60, 95%CI
1.23-2.08, p<0.001), BMI (OR 1.04, 95%CI 1.02-1.06, per 1kg/m2 increase,
p<0.001) and treatment with 1st generation ADPri (OR 3.12, 95%CI 2.22-4.39,
p<0.001). After platelet function testing, ADPri was switched from 1st to 2nd
generation in 37% of patients with HPR compared with 10% of patients with thera-
peutic platelet reactivity (TPR), while 8% of patients with HPR and 6% of patients
with TPR were switched from a 2nd to 1st generation ADPri.
Conclusions: While the value of modifying treatment based on platelet function
testing remains unclear, we found that ADPri therapy was frequently altered when
HPR was detected. Further evaluation of clinical outcomes associated with modiﬁ-
cation of ADPri therapy among PCI treated MI patients with HPR is warranted.acts/POSTER/Antiplatelets and Antithrombins B47
